文献速递乳腺技术与安全US

超声造影诊断乳腺恶性非肿块病变的价值及诊断标准探索

The role of contrast-enhanced ultrasound in the diagnosis of malignant non-mass breast lesions and exploration of diagnostic criteria.
PubMed 文献 · Br J Radiol · 2021-02-09

本研究纳入116例患者共119个常规超声检出的非肿块乳腺病变,以病理为参考标准,比较良恶性病变的超声造影增强特征,并通过二元逻辑回归建立超声造影诊断标准。增强程度(OR=5.75)、增强范围(OR=4.25)和放射状或穿支血管(OR=7.54)为独立诊断指标;超声造影特异度74.6%高于BI-RADS-US的30.2%,但敏感度80.4%低于BI-RADS-US的100%。超声造影联合BI-RADS-US的敏感度和特异度分别为94.6%和77.8%,AUC为0.885。

要点

  • 增强程度、增强范围和放射状或穿支血管是恶性非肿块乳腺病变的独立超声造影诊断指标。
  • 超声造影诊断恶性非肿块病变特异度74.6%,高于BI-RADS-US的30.2%,但敏感度80.4%低于BI-RADS-US的100%。
  • 超声造影联合BI-RADS-US的AUC为0.885,敏感度94.6%、特异度77.8%。

关键影像表现/征象

  • 病理结果显示良性非肿块病变63个、恶性非肿块病变56个。
  • 增强程度(OR=5.75,p=0.003)、增强范围(OR=4.25,p=0.005)和放射状或穿支血管(OR=7.54,p=0.003)为纳入建立超声造影诊断标准的独立诊断指标。

诊断标准与关键数值

  • BI-RADS-US诊断恶性非肿块乳腺病变的敏感度和特异度分别为100%和30.2%,AUC为0.819。
  • 超声造影诊断标准的敏感度和特异度分别为80.4%和74.6%,AUC为0.775。
  • BI-RADS-US联合超声造影的敏感度和特异度分别为94.6%和77.8%,AUC为0.885。

临床应用与阅片要点

  • 作者认为超声造影联合BI-RADS-US对恶性非肿块乳腺病变具有较高诊断价值,是兼具较高敏感度和特异度的有效诊断工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess the value of contrast-enhanced ultrasound (CEUS) for diagnosing malignant non-mass breast lesions (NMLs) and to explore the CEUS diagnostic criteria.

METHODS: A total of 116 patients with 119 NMLs detected by conventional US were enrolled. Histopathological results were used as the reference standard. The enhancement characteristics of NMLs in CEUS were compared between malignant and benign NMLs. The CEUS diagnostic criteria for malignant NMLs were established using independent diagnostic indicators identified by binary logistic regression analysis. The diagnostic performance of Breast Imaging Reporting and Data System-US (BI-RADS-US), CEUS, and BI-RADS-US combined with CEUS was evaluated and compared.

RESULTS: Histopathological results showed 63 and 56 benign and malignant NMLs. Enhancement degree (OR = 5.75, p = 0.003), enhancement area (OR = 4.25, p = 0.005), and radial or penetrating vessels (OR = 7.54, p = 0.003) were independent diagnostic indicators included to establish the CEUS diagnostic criteria. The sensitivity and specificity of BI-RADS-US, CEUS, and BI-RADS-US combined with CEUS were 100 and 30.2%, 80.4 and 74.6%, and 94.6 and 77.8%, respectively; the corresponding areas under the receiver operating characteristic curve (AUC) were 0.819, 0.775, and 0.885, respectively.

CONCLUSIONS: CEUS has a high specificity in malignant NML diagnosis based on the diagnostic criteria including enhancement degree, enhancement area, and radial or penetrating vessels, but with lower sensitivity than BI-RADS-US. The combination of CEUS and BI-RADS-US is an effective diagnostic tool with both high sensitivity and specificity for the diagnosis of malignant NMLs.

ADVANCES IN KNOWLEDGE: In this study, we assessed the diagnostic value of CEUS for malignant NMLs and constructed a feasible diagnostic criterion. We further revealed that the combination of CEUS and BI-RADS-US has a high diagnostic value for malignant NMLs.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Zhang F, Jin L, Li G, et al. The role of contrast-enhanced ultrasound in the diagnosis of malignant non-mass breast lesions and exploration of diagnostic criteria. Br J Radiol. 2021. PMID: 33560894. doi:10.1259/bjr.20200880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。